[Use of streptodecase in acute myocardial infarct].
This if the first time in the world that streptodecase has been used as a fibrinolytic drug during the first hours of clinical manifestations of myocardial infarction in 12 patients. The drug was given once, intravenously in the dose of 3,000,000 units. Favourable action of the drug on the clinical manifestations of the disease and its prolonged activating effect on the blood fibrinolysis have been established. The advantages of streptodecase over streptokinase in the treatment of acute myocardial infarction are discussed.
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004562:Electrocardiography; D004800:Enzymes, Immobilized / Q000008:administration & dosage*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000008:administration & dosage*; D013997:Time Factors
D003692:Delayed-Action Preparations; D004800:Enzymes, Immobilized; D013300:Streptokinase
Primenenie streptodekazy pri ostrom infarkte miokarda.